Monte Rosa Therapeutics, Inc. GLUE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| External Research And Development Expense by Product | ||||||
| CCNE One | $1.7M— | —— | —— | —— | $762K— | |
| MRT Eight One Zero Two | $6.78M-27.1% | $9.31M+27.4% | $7.31M+350% | $1.62M-13.8% | $1.88M-64.6% | |
| MRT Six One Six Zero | $11K-98.3% | $637K-55.9% | $1.44M-2.2% | $1.48M-62.9% | $3.98M-54.5% | |
| MRT Two Three Five Nine | $2.38M-8.3% | $2.6M+19.3% | $2.18M-3.0% | $2.24M+15.3% | $1.95M-34.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Monte Rosa Therapeutics, Inc. break its business down?
- Monte Rosa Therapeutics, Inc. (GLUE) reports external research and development expense by product across 4 parts — CCNE One, MRT Eight One Zero Two, MRT Six One Six Zero and MRT Two Three Five Nine. Each is extracted from the segment footnotes and tracked over time.
- Where does Monte Rosa Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Monte Rosa Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
